Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
MTX placebo
DRUG
2 trials
Sponsors
Chugai Pharmaceutical
, Eli Lilly and Company
Conditions
Rheumatoid Arthritis
Phase 3
Comparative Study (Double-Blind) of MRA for Rheumatoid Arthritis (RA)
Completed
NCT00144521
Chugai Pharmaceutical
Rheumatoid Arthritis
Start: 2004-02-29
End: 2006-04-30
Updated: 2009-02-02
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
Completed
NCT01711359
Eli Lilly and Company
Rheumatoid Arthritis
Start: 2012-11-30
End: 2015-08-31
Updated: 2019-09-19
Related Papers
Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis up to 6.5 years of treatment: results of a long-term study.
2024-10-01
4 citations
Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy
RMD Open
2022-03-01
25 citations
Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database.
2021-10-27
107 citations
Radiographic Progression of Structural Joint Damage Over 5 Years of Baricitinib Treatment in Patients With Rheumatoid Arthritis: Results From RA-BEYOND
The Journal of Rheumatology
2021-09-15
7 citations
Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis
Arthritis Research & Therapy
2020-05-15
16 citations
Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: An integrated analysis of Phases 2 and 3 trials
Modern Rheumatology
2019-02-20
54 citations
Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment
The Journal of Rheumatology
2018-09-15
251 citations
Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies.
2018-02-20
44 citations
Relationship between disease activity and patient-reported outcomes in rheumatoid arthritis: Post hoc analyses of overall and Japanese results from two phase 3 clinical trials.
2018-02-02
13 citations
Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment.
2017-09-18
46 citations
Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study.
2016-09-29
272 citations